Stocks · News reference
'HHS launches project to speed up clinical trials' - Axios
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand
The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.
8-K filing — Fortrea Holdings Inc. (FTRE)
Filed: 2026-09-30 AccNo: 0001628280-26-063970 Size: 177 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
UBS Initiates Coverage On Fortrea Holdings with Neutral Rating, Announces Price Target of $22
Fortrea Reinstates Jason Knoblauch As CFO
David Smith, a current director on the Board, had acted as Interim Chief Financial Officer and principal financial officer during Mr. Knoblauch’s leave of absence. In connection with Mr. Knoblauch’s reinstatement, Mr.